Page last updated: 2024-08-23

epirubicin and Ventricular Dysfunction

epirubicin has been researched along with Ventricular Dysfunction in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berriolo-Riedinger, A; Brunotte, F; Cochet, A; Cottin, Y; Coudert, B; Dygai-Cochet, I; Fumoleau, P; Quilichini, G; Toubeau, M; Touzery, C	1

Trials

1 trial(s) available for epirubicin and Ventricular Dysfunction

Article	Year
Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast cancer research and treatment, 2011, Volume: 130, Issue:3 Topics: Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Staging; Prognosis; Radionuclide Imaging; Reproducibility of Results; Risk Factors; Trastuzumab; Ventricular Dysfunction	2011

Article

Year

Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.

Breast cancer research and treatment, 2011, Volume: 130, Issue:3

Topics: Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Staging; Prognosis; Radionuclide Imaging; Reproducibility of Results; Risk Factors; Trastuzumab; Ventricular Dysfunction

2011